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Abstract
Background: Both paclitaxel (P) and carboplatin (C) have significant activity in non-small cell lung cancer
(NSCLC). The weekly administration of P is active, dose intense, and has a favorable toxicity profile. We
retrospectively reviewed the data of 51 consecutive patients receiving C and day 1 and 8 P chemotherapy (CT)
regimen in advanced stage NSCLC to evaluate the efficacy and toxicity.
Methods: Patients treated in our institutions having pathologically proven NSCLC, no CNS metastases, adequate
organ function and performance status (PS) ECOG 0–2 were given P 112.5 mg/m2 intravenously (IV) over 1 hour
on day 1 and 8, followed by C AUC 5 IV over 1 hour, repeated in every three weeks. PC was given for maximum
of 6 cycles.
Results: Median age was 58 (age range 39–77) and 41 patients (80%) were male. PS was 0/1/2 in 29/17/5 patients
and stage was IIIA/IIIB/IV in 3/14/34 patients respectively. The median number of cycles administered was 3 (1–
6). Seven patients (14%) did not complete the first 3 cycles either due to death, progression, grade 3
hypersensitivity reactions to P or lost to follow up. Best evaluable response was partial response (PR) in 45% and
stable disease (SD) in 18%. Twelve patients (24%) received local RT. Thirteen patients (25%) received 2nd line
CT at progression. At a median follow-up of 7 months (range, 1–20), 25 (49%) patients died and 35 patients (69%)
progressed. Median overall survival (OS) was 11 ± 2 months (95% CI; 6 to 16), 1-year OS ratio was 44%. Median
time to progression (TTP) was 6 ± 1 months (95% CI; 4 to 8), 1-year progression free survival (PFS) ratio was
20%. We observed following grade 3 toxicities: asthenia (10%), neuropathy (4%), anorexia (4%), anemia (4%),
hypersensitivity to P (2%), nausea/vomiting (2%), diarrhea (2%) and neutropenia (2%). Two patients (4%) died of
febrile neutropenia. Doses of CT were reduced or delayed in 12 patients (24%).
Conclusions: P on day 1 and 8 and C every three weeks is practical and fairly well tolerated outpatient regimen.
This regimen seems to be comparably active to regimens given once in every three weeks.
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Background
Lung cancer is the leading cause of cancer related deaths
all around the world. About 80% of all lung cancers are
non-small cell lung cancer (NSCLC) and more than 50%
of these patients present with locally advanced or meta-
static disease.
Meta-analysis of several randomized trials have demon-
strated a modest survival advantage for treatment with cis-
platin-based regimens in patients with advanced stages of
NSCLC [1,2]. Furthermore, chemotherapy (CT) also has
been shown to ameliorate symptoms and increase quality
of life [3]. Addition of second generation CT regimens
with cisplatin or carboplatin plus newer agents, such as
taxanes (paclitaxel and docetaxel), gemcitabine, vinorel-
bine have shown increased response rates and 1-year sur-
vival ratios, but overall survivals have not been altered [4-
6].
Being the first of the taxane antimicrotubule agents, pacl-
itaxel (P) demonstrated overall response rates of 21–24%
and 1-year survival rates of 37–42% in the phase II trials
where it was used as a single agent [7,8]. Antiangiogenic
effect of P has also been reported (9). Carboplatin (C) has
also demonstrated comparable activity but better toxicity
profile than cisplatin in the treatment of advanced NSCLC
[10,11].
P and C used in combined chemotherapy regimens have
significant activity in NSCLC. PC given every three weeks
is considered to be one of the standard regimens being
used worldwide [10]. The weekly administration of P is
active, dose intense, and has a favorable toxicity profile.
To evaluate the efficacy and toxicity of C and day 1 and 8
P in advanced stage NSCLC, we retrospectively reviewed
51 consecutive patients receiving this CT regimen.
Methods
All patients with stage III or IV NSCLC treated at Medical
Oncology Units of Marmara University Hospital, Dr. Lutfi
Kirdar Research and Training Hospital, SSK Sureyyapasa
Chest and Cardiovascular Diseases Hospital and Gulhane
Military Medical Academy Hospital within July 2002 and
August 2003 were considered for this protocol. Eligible
patients were required to have pathologically proven
NSCLC, stage III or IV disease at presentation or pro-
gressed after surgery, performance status (PS) ECOG 0–2,
objective measurable disease, adequate bone marrow
functions (white blood cell count ≥ 3500/mm3, hemo-
globin ≥ 9 g/dl, and platelet count ≥ 100000/mm3), and
adequate liver functions (bilirubin ≤ 1.5 mg/dl and
alanine aminotransferase ≤ 2 times upper limit of normal
and ≤ 5 times upper limit of normal for the patients with
liver metastases) and kidney functions (creatinine ≤ 1.5
mg/dl). No prior chemotherapy or radiotherapy (except
to bone metastases for palliation) was allowed. Patients
presenting with known central nervous system (CNS) dis-
ease and uncontrolled cardiac arrhythmia were excluded
from this study and they were treated with other chemo-
therapy regimens (single agent or combination of plati-
num and vinorelbine, docetaxel or gemcitabine).
Patients were treated with P (112.5 mg/m2/day) on days 1
and 8, followed by C (AUC 5/6) on day 1, repeated in
every three weeks. Both drugs were diluted in 250 ml of
normal saline and given intravenously (IV) over 1 hour.
No growth factors were administered. Anti-allergic pre-
medication included IV diphenhydramine 50 mg, IV ran-
itidine 50 mg, and IV dexamethasone 16 mg 1 hour prior
to P administration.
Toxicity evaluation and routine physical examination
were performed in every 3 weeks. Complete blood count
(CBC) was done on days 1 and 8 of each cycle, liver and
kidney function tests on every 2 cycles. Cranial computed
tomography scans (CT), magnetic resonance imaging
(MRI) and bone scans were performed as clinically indi-
cated. Side effects of the treatment were graded according
to the National Cancer Institute Common Toxicity Crite-
ria (CTC), version 2.0 [12]. Colony stimulating factors
were not used.
Response was evaluated with CT of chest and/or abdomen
on every 3rd cycle and standard World Health Organiza-
tion (WHO) criteria were used to determine response
[13]. Independent of the stage at presentation, patients
having partial response (PR), stable disease (SD) or pro-
gressive disease (PD) during CT were consulted for radio-
therapy (RT) for either primary treatment or palliation.
The treatment was stopped for patients with PD. Patients
with CR, PR or SD after 3 cycles continued their treatment.
PC was given for maximum of 6 courses to the patients
having PR or SD.
Patients were irradiated with CT based treatment planning
and multiple fields arrangements with custom blocking to
all fields and involved hilar and mediastinal lymph nodes
up to 40–41.4 Gy. Boost was given to the primary tumor.
Total dose of 60–61.2 Gy was administered in 1.8–2 Gy
daily fractions for 5 days a week and completed in 6
weeks.
Statistical analysis
Overall survival (OS) and time to progression (TTP) were
assessed from the date of diagnosis to the date of death
(any cause) and the date of objective disease progression
(death was considered a progression event in patients
who died before disease progression), respectively. Sur-
vival rates were calculated by using the Kaplan-Meier
method [14]. The pre-specified prognostic value of age (<BMC Cancer 2005, 5:10 http://www.biomedcentral.com/1471-2407/5/10
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60 years vs. ≥ 60 years), gender, PS (0 vs. 1–2), histology
(adenocarcinoma vs. squamous cell vs. NSCLC), stage (III
vs. IV), smoking history (present vs. absent), and response
after third cycle of CT (PR vs. other) were evaluated in uni-
variate and multivariate analyses. Log rank test was used
for univariate survival analysis [15]. The multivariate Cox
proportional hazard model was applied to identify the
variables that can independently influence survival.
Results
The data of 51 patients receiving PC treatment were col-
lected retrospectively between July 2002 and November
2003. Median follow-up time was 7 months (range, 1–
20). Median age was 58 years (range 39–77) and 45% of
patients were 60 year-old or above. Eighty percent were
male. PS was 0 in 57% of patients and 67% had presented
with stage IV disease. Most frequent metastatic sites were
the other lung (17), adrenal (10), liver (7) and bone (7).
Eighty-two percent of the patients had smoking history,
median of which was 40 pack-years (range, 0–135).
Patients' baseline characteristics are presented in Table 1.
The median number of cycles administered was 3 (range,
1–6). Seven patients (14%) did not complete the first 3
cycles either due to death (2), progression (3), grade 3
hypersensitivity reaction to P (1) or lost to follow up (1).
Best evaluable response was PR in 45% and SD in 18%.
Only 22 (43%) patients continued the treatment after the
3rd course. At the end of treatment of these 22 patients 10
(46%) had PR and 6 (27%) had SD, but the other 6
patients (27%) had PD. No complete remission was seen.
Twelve patients (24%) received local RT and 4 of these
patients were given low dose gemcitabine (75 mg/m2/
week × 5–6 weeks) as radiosensitizing agent. Of these 12
patients 3 presented with stage IIIA and all had PR to PC
therapy. But of the 5 patients with IIIB disease who were
irradiated only one patient had PR, 3 had SD and another
one had PD after the 3 cycles of CT. Four patients with
Table 1: Patient characteristics
Characteristics Number of patients Percentage (%)
Age, years
Median 58
Range (39–77)
Gender
Male 41 80
Female 10 20
Performance Status
02 9 5 7
11 7 3 3
25 1 0
Stage
IIIA 3 6
IIIB 14 27
IV 34 67
Histology
Adenocarcinoma 16 31
Squamous cell carcinoma 18 36
NSCLC 17 33
Sites of metastases
Lung 17 50
Adrenal 10 29
Bone 7 21
Liver 7 21
Distant LAP 3 9
Number of metastatic organs
12 4 7 1
29 2 6
31 3
Smoking history
Yes 42 82
No 9 18
Table 2: Response rates and second line treatments with CT and 
RT
Number of patients Percentage (%)
Number of PC received
12 4
25 1 0
32 0 3 9
43 6
53 6
61 8 3 5
Response to PC
PR 23 45
SD 9 18
PD 16 31
Not assessed 3 6
Second line CT 13
G ± Cis / C 10 78
Other 3 23
Local RT 12
Stage IIIA 3 25
Stage IIIB 5 42
Stage IV 4 33
CT: Chemotherapy; RT: Radiotherapy; P: Paclitaxel; C: Carboplatin; 
G: Gemcitabine; Cis: CisplatinBMC Cancer 2005, 5:10 http://www.biomedcentral.com/1471-2407/5/10
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stage IV were offered RT for palliation. Thirteen patients
(25%) received 2nd line CT at progression and of those
only one patient had PR and another SD to this treatment.
For 2nd line CT gemcitabine ± cisplatin or C was used in
10 patients (78%) and the rest received other agents like
vinorelbine, C or docetaxel. Details of this data can be
seen in Table 2.
At a median follow-up of 7 months 25 (49%) patients
died and 35 patients (69%) progressed. Median OS time
was 11 ± 2 months (95% CI; 6 to16), 1-year OS ratio was
44% (Figure 1). Median TTP was 6 ± 1 months (95% CI;
4 to 8), 1-year progression free survival (PFS) ratio was
20% (Figure 2).
The most frequent toxicity related symptoms were asthe-
nia (61%), neuropathy (42%) and anorexia (35%). We
observed the following grade 3 toxicities: asthenia (10%),
neuropathy (4%), anorexia (4%), anemia (4%), hyper-
sensitivity to P (2%), nausea/vomiting (2%), diarrhea
(2%) and neutropenia (2%). Two patients (4%) died of
febrile neutropenia due to a three day delay in referral to
hospital after the onset of fever > 38°, although they were
warned about the side effects of the therapy. Doses of CT
was reduced or delayed in 12 patients (24%) (Table 3).
Univariate analysis showed that patients presenting with
PS of 0, stage III disease and having PR after the 3rd cycle
of PC have statistically higher OS (p = 0.015, p = 0.018
and p = 0.047, respectively)(Table 4). PS and stage of the
disease at presentation and response to the CT after the
3rd cycle were also statistically significant independent
prognostic factors influencing the OS in multivariate Cox
regression analysis (p = 0.034, p = 0.049 and 0.021,
respectively).
Discussion
Paclitaxel and carboplatin have been shown to be an effec-
tive and well tolerated CT regimen in advanced stage
NSCLC [10]. PC given once in every three weeks is one of
the most widely used standard schedules worldwide
based on the spectrum of activity and the ease of admin-
istration. This regimen results in an objective response
rate of 17–25% with a median survival time of 8 months
in stage IIIB and IV NSCLC patients. The major toxicities
of this regimen are neuropathy and neutropenia [10,16].
Weekly P is a relatively new strategy for lowering toxicity
and increasing dose-intensity and possibly efficacy. Alva-
rez et al. have used weekly P on patients who progressed
or remained stable on P administered in every three weeks
and reported that it can induce response in 62.5% of
patients with low toxicity [17]. Akerley has also studied
weekly P administration on phase I and phase II settings
[18-20]. They started with a P dose of 175 mg/m2/week ×
6 every 8 weeks in the phase II trial, but they had to reduce
the dose up to 50% due to primarily neutropenia and neu-
ropathy with extended therapy. Therefore, they recom-
mended 150 mg/m2 as the weekly dose of P [20].
Weekly dose of P in combination with cisplatin or C had
been administered in NSCLC patients by Belani et al.
[21,22]. They used this combination in a multicenter
Overall survival Kaplan-Meier curve Figure 1
Overall survival Kaplan-Meier curve
Progression free survival curve Figure 2
Progression free survival curve
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three arm trial in 401 patients with stage IIIB and IV dis-
ease [21]. In that trial P was given 100 mg/m2/week for 3
weeks out of 4 week cycles in arms I and II, with C either
AUC of 6 on day 1 or AUC of 2 on days 1, 8 and 15 of each
of four 4-week cycles. Arm III of this trial consisted of P
(150 mg/m2) and C (AUC = 2) given weekly for 6 out of
8 weeks for a total of two cycles. Greater percentage of the
patients on arm I received intended CT (30% of P and
55% of C) compared with the other arms (28–29% of P
and 21–22% of C). Patients on arm I received more than
half of the planned C dose. The main reasons for discon-
tinuation of therapy were progression of disease (31%)
and adverse events (15%). Median time to progression
and median survival time were significantly higher for
arm I than arm II for patients with stage IIIB disease. Per-
formance status of the patients was also statistically
related to the survival times. Patients with PS-0/1 had
longer median PFS with treatment arm I than arm II and
patients with PS-2 had higher median OS with arm I than
arm II. Although arm I was the most easily tolerable
schedule between the three arms, grade 3 or 4 neutropenia
was observed in 22% of the patients included. In this trial
treatment arm I had a response rate of 32%, median TTP
of 6.9 months, median OS time of 11.3 months and 1-
year survival rate of 47%. In our study, response rate was
45%, median TTP was 6 months, median OS time was 11
months and 1-year survival rate was 44%. The majority of
our patients comprised of stage IIIB and IV disease, similar
to the patient group in Belani's study resulting in similar
response rates and survival data [21]. These results also
seem more effective than the regimen given once in every
three weeks of the same drugs [10,16].
We used the standard dose of P (225 mg/m2) given in
every three weeks and divided into two consecutive weeks.
C dose was calculated according to Calvert formulation
with an AUC of 5. This is a lower dose than the dose of C
being used in other phase III trials in the literature. In our
study only 4 patients (8%) had dose reduction of 10%
and 16% of patients had treatment delays of 1 week
because of side effects. According to this data, 76% of
patients have received the total planned doses of the drugs
on scheduled date. Two patients (4%) died of febrile neu-
tropenia due to a three day delay in referral to hospital
after the onset of fever > 38°, although they were warned
about the side effects of the therapy. It is worth mention-
Table 3: Toxicities seen during PC treatment
Toxicity Overall (%) Grade 1–2 (%) Grade 3 (%) Grade 4 (%)
Neutropenia 12 10 2
Febrile neutropenia 4 4
Anemia 22 18 4
Asthenia/Fatigue 61 51 10
Neuropathy 42 38 4
Anorexia 35 31 4
Arthralgia 31 31
Nausea/Vomiting 22 20 2
D i a r r h e a 862
Mucositis 6 6
Hypersensitivity to P 2 2
Table 4: Prognostic factors in the univariate analyses for overall 
survival
Variables Median OS (months) p
Age
60 years and over 11 ± 2 0.87
Less than 60 years 12 ± 3
Gender
Male 9 ± 3 0.22
Female 15 ± 6
PS
0 15 ± 3 0.015*
1–2 6 ± 2
Histology
Adenocarcinoma 15 ± 5 0.73
Squamous cell 13 ± 7
NSCLC 11 ± 3
Stage at presentation
III NR† 0.018*
IV 9 ± 2
Smoking history
Yes 9 ± 2 0.20
No NR†
Response after 3 cycles of CT
PR 13 ± 2 0.047*
Other 6 ± 1
* Statistically significant
† Mean OS is 15 ± 2 months
PS: ECOG Performance status; NR: Not reached; CT: ChemotherapyBMC Cancer 2005, 5:10 http://www.biomedcentral.com/1471-2407/5/10
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ing that none of our patients received any colony stimu-
lating factors.
We have shown that the response to treatment after the
third cycles of CT was one of the independent prognostic
factors influencing OS. It has already been reported by
Socinski et al. that 4 cycles of CT give the maximum ben-
efit which could be obtained from CT in patients with
stage IIIB and IV NSCLC [23]. Smith et al. also studied 3
cycles versus 6 cycles of CT in the same group of patients
and failed to show any survival advantage for longer treat-
ment durations [24]. In addition, there was an increase in
the side effects such as fatigue, nausea and vomiting in the
patients receiving six courses.
It has been shown that PC combination has relatively
mild toxicity profile. Belani et al. observed in their phase
I trial that patients who received the PC combination in
every three weeks experienced less severe thrombocytope-
nia than would be expected from C alone. In the view of
this finding they suggested that there was a platelet-spar-
ing effect of P on the dose-limiting thrombocytopenia
side effect of C [25]. This phenomenon was also shown by
Akerley [18] and Kearns [26]. Akerley reported that plate-
let counts rose by 17000/mL/week with weekly P admin-
istration [18]. Belani also speculated on the mechanism
for this platelet protective effect and said that it may
involve some alteration of megakaryocytopoiesis or
thrombocytopoiesis, which could result in increased lev-
els of endogenous thrombopoietin or other cytokines
[27]. Kearns et al. suggested that prior exposure to P may
suppress the inhibition of platelet formation, which is
associated with C [26]. None of our patients experienced
thrombocytopenia during our CT treatment with day 1
and 8 P with day 1 C on every three weeks.
One of the most frequent side effects during our treatment
was neuropathy, but it was usually mild (Grade 1 or 2),
only 4% of our patients experiencing grade 3 sensory neu-
ropathy. Grade 3 or 4 neuropathy has been reported to be
10–20% in schedules given every three weeks [10,16]. Bel-
ani reported 3–13% of grade 3 or 4 neuropathy, but the
incidence was lower for arms 1 (P given weekly and C
every four weeks) and 2 (P and C both given weekly), at
only 5% and 3%, respectively [21]. This result for arm 1 is
similar to the neuropathy rate in our study.
Besides the reduced toxicity, weekly administration of P
also increases the drugs' anti-angiogenic and apoptotic
effects. The metronomic schedule of P has been studied
widely during the last few years. P had been shown to
inhibit endothelial cell proliferation, motility, invasive-
ness, and cord formation both in vitro and in vivo
Matrigel assays in a dose dependent manner [9]. Belani et
al. randomized the patients having objective response to
weekly P and C regimens into two arms (maintenance and
observation arms). Patients were either treated with
weekly P (70 mg/m2/week × 3 weeks out of four weeks
cycles) in maintenance arm or observed until disease pro-
gression has occurred. They reported that the mainte-
nance arm was compared to the observation arm and had
a median PFS of 38 weeks vs. 29 weeks, median OS of 75
weeks vs. 60 weeks, respectively [21]. Although there was
not a statistically significant difference between the two
arms, authors concluded that this might be a result of low
number of patients enrolled in the study (only 65 patients
in each arm). It is not yet known whether these responses
have an anti-angiogenic basis, or whether such responses
will translate into a significant prolongation of survival.
Although our study is a retrospective analysis, it is one of
the few manuscripts on this PC scheduling in NSCLC in
the literature.
Conclusions
Paclitaxel on day 1 and 8 and carboplatin every three
weeks is a practical and fairly well tolerated outpatient
regimen. This regimen seems to be comparably active to
regimens given every three weeks. This schedule needs to
be further evaluated by well planned randomized phase
III trials where it could be compared to the standard regi-
mens in patients with advanced stage NSCLC.
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